ICM Co. Ltd.
🇰🇷South Korea
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Long Term Follow-up Study of Subjects Who Received ICM-203 or Matching Placebo
- Conditions
- Osteoarthritis, Knee
- Interventions
- Genetic: ICM-203Drug: Placebo
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- ICM Co. Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05752032
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Barwon Health, Geelong, Victoria, Australia
A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis.
Phase 1
Not yet recruiting
- Conditions
- Osteoarthritis, Knee
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- ICM Co. Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT05454566
News
No news found